Your browser doesn't support javascript.
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London.
Russell, Beth; Moss, Charlotte; Papa, Sophie; Irshad, Sheeba; Ross, Paul; Spicer, James; Kordasti, Shahram; Crawley, Danielle; Wylie, Harriet; Cahill, Fidelma; Haire, Anna; Zaki, Kamarul; Rahman, Fareen; Sita-Lumsden, Ailsa; Josephs, Debra; Enting, Deborah; Lei, Mary; Ghosh, Sharmistha; Harrison, Claire; Swampillai, Angela; Sawyer, Elinor; D'Souza, Andrea; Gomberg, Simon; Fields, Paul; Wrench, David; Raj, Kavita; Gleeson, Mary; Bailey, Kate; Dillon, Richard; Streetly, Matthew; Rigg, Anne; Sullivan, Richard; Dolly, Saoirse; Van Hemelrijck, Mieke.
  • Russell B; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Moss C; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Papa S; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Irshad S; School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Ross P; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Spicer J; School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Kordasti S; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Crawley D; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Wylie H; School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Cahill F; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Haire A; Haematology Department, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, United Kingdom.
  • Zaki K; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Rahman F; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Sita-Lumsden A; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Josephs D; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Enting D; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Lei M; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Ghosh S; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Harrison C; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Swampillai A; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Sawyer E; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • D'Souza A; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Gomberg S; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Fields P; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Wrench D; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Raj K; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Gleeson M; Haematology Department, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, United Kingdom.
  • Bailey K; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Dillon R; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Streetly M; School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
  • Rigg A; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Sullivan R; Guy's and St Thomas' NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom.
  • Dolly S; Haematology Department, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, United Kingdom.
  • Van Hemelrijck M; Haematology Department, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, United Kingdom.
Front Oncol ; 10: 1279, 2020.
Article in English | MEDLINE | ID: covidwho-706935
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

Background:

There is insufficient evidence to support clinical decision-making for cancer patients diagnosed with COVID-19 due to the lack of large studies.

Methods:

We used data from a single large UK Cancer Center to assess the demographic/clinical characteristics of 156 cancer patients with a confirmed COVID-19 diagnosis between 29 February and 12 May 2020. Logistic/Cox proportional hazards models were used to identify which demographic and/or clinical characteristics were associated with COVID-19 severity/death.

Results:

128 (82%) presented with mild/moderate COVID-19 and 28 (18%) with a severe case of the disease. An initial cancer diagnosis >24 months before COVID-19 [OR 1.74 (95% CI 0.71-4.26)], presenting with fever [6.21 (1.76-21.99)], dyspnea [2.60 (1.00-6.76)], gastro-intestinal symptoms [7.38 (2.71-20.16)], or higher levels of C-reactive protein [9.43 (0.73-121.12)] were linked with greater COVID-19 severity. During a median follow-up of 37 days, 34 patients had died of COVID-19 (22%). Being of Asian ethnicity [3.73 (1.28-10.91)], receiving palliative treatment [5.74 (1.15-28.79)], having an initial cancer diagnosis >24 months before [2.14 (1.04-4.44)], dyspnea [4.94 (1.99-12.25)], and increased CRP levels [10.35 (1.05-52.21)] were positively associated with COVID-19 death. An inverse association was observed with increased levels of albumin [0.04 (0.01-0.04)].

Conclusions:

A longer-established diagnosis of cancer was associated with increased severity of infection as well as COVID-19 death, possibly reflecting the effects a more advanced malignant disease has on this infection. Asian ethnicity and palliative treatment were also associated with COVID-19 death in cancer patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Prognostic study Topics: Long Covid Language: English Journal: Front Oncol Year: 2020 Document Type: Article Affiliation country: Fonc.2020.01279

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Prognostic study Topics: Long Covid Language: English Journal: Front Oncol Year: 2020 Document Type: Article Affiliation country: Fonc.2020.01279